Global transcriptome analysis reveals that poly(ADP-ribose) polymerase 1 regulates gene expression through EZH2

Molecular and Cellular Biology

Volumn 35, Issue 23, 2015, Pages 3934-3944

  Martin, Kayla A ^a   Cesaroni, Matteo ^a,b   Denny, Michael F ^a   Lupey, Lena N ^a   Tempera, Italo ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Janssen R and D   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; HISTONE LYSINE METHYLTRANSFERASE; LYSINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OLAPARIB; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR E2F4; TRANSCRIPTION FACTOR EZH2; EZH2 PROTEIN, HUMAN; HISTONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN;

ARTICLE; CATALYSIS; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME INHIBITION; GENE CONTROL; GENE EXPRESSION; GENE ONTOLOGY; GENE SILENCING; HISTONE METHYLATION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REPRESSOR GENE; TRANSCRIPTOMICS; CELL LINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHYLATION;

CELL LINE; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HISTONES; HUMANS; METHYLATION; POLY (ADP-RIBOSE) POLYMERASE-1; POLY(ADP-RIBOSE) POLYMERASES; POLYCOMB REPRESSIVE COMPLEX 2; PROMOTER REGIONS, GENETIC;

EID: 84946196599     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00635-15     Document Type: Article

References (53)

1. Strahl BD, Allis CD. 2000. The language of covalent histone modifications. Nature 403:41-45. http://dx.doi.org/10.1038/47412.
2. Jenuwein T, Allis CD. 2001. Translating the histone code. Science 293:1074-1080. http://dx.doi.org/10.1126/science.1063127.
3. Berger NA, Sikorski GW. 1981. Poly(adenosine diphosphoribose) synthesis in ultraviolet-irradiated xeroderma pigmentosum cells reconstituted with Micrococcus luteus UV endonuclease. Biochemistry 20:3610-3614. http://dx.doi.org/10.1021/bi00515a047.
4. Kraus WL. 2008. Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. Curr Opin Cell Biol 20:294-302. http://dx.doi.org/10.1016/j.ceb.2008.03.006.
5. Ji Y, Tulin AV. 2010. The roles of PARP1 in gene control and cell differentiation. Curr Opin Genet Dev 20:512-518. http://dx.doi.org/10.1016/j.gde.2010.06.001.
6. Krishnakumar R, Kraus WL. 2010. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 39:8-24. http://dx.doi.org/10.1016/j.molcel.2010.06.017.
7. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. 1999. Poly(ADP-ribosyl) ation reactions in the regulation of nuclear functions. Biochem J 342(Pt 2):249-268. http://dx.doi.org/10.1042/0264-6021:3420249.
8. Ogata N, Ueda K, Kawaichi M, Hayaishi O. 1981. Poly(ADP-ribose) synthetase, a main acceptor of poly(ADP-ribose) in isolated nuclei. J Biol Chem 256:4135-4137.
9. Huletsky A, de Murcia G, Muller S, Hengartner M, Ménard L, Lamarre D, Poirier GG. 1989. The effect of poly(ADP-ribosyl)ation on native and H1-depleted chromatin. A role of poly(ADP-ribosyl)ation on core nucleosome structure. J Biol Chem 264:8878-8886.
10. Kraus WL, Lis JT. 2003. PARP goes transcription. Cell 113:677-683. http://dx.doi.org/10.1016/S0092-8674(03)00433-1.
11. Mathis G, Althaus FR. 1987. Release of core DNA from nucleosomal core particles following (ADP-ribose)n-modification in vitro. Biochem Biophys Res Commun 143:1049-1054. http://dx.doi.org/10.1016/0006-291X(87)90358-5.
12. Poirier GG, de Murcia G, Jongstra-Bilen J, Niedergang C, Mandel P. 1982. Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of chromatin structure. Proc Natl Acad Sci U S A 79:3423-3427. http://dx.doi.org/10.1073/pnas.79.11.3423.
13. Tulin A, Spradling A. 2003. Chromatin loosening by poly(ADP)-ribose polymerase (PARP) at Drosophila puffloci. Science 299:560-562. http://dx.doi.org/10.1126/science.1078764.
14. Izhar L, Adamson B, Ciccia A, Lewis J, Pontano-Vaites L, Leng Y, Liang AC, Westbrook TF, Harper JW, Elledge SJ. 2015. A systematic analysis of factors localized to damaged chromatin reveals PARP-dependent recruitment of transcription factors. Cell Rep 11:1486-1500. http://dx.doi.org/10.1016/j.celrep.2015.04.053.
15. Krishnakumar R, Kraus WL. 2010. PARP-1 regulates chromatin structure and transcription through a KDM5B-dependent pathway. Mol Cell 39:736-749. http://dx.doi.org/10.1016/j.molcel.2010.08.014.
16. Zampieri M, Passananti C, Calabrese R, Perilli M, Corbi N, De Cave F, Guastafierro T, Bacalini MG, Reale A, Amicosante G, Calabrese L, Zlatanova J, Caiafa P. 2009. Parp1 localizes within the Dnmt1 promoter and protects its unmethylated state by its enzymatic activity. PLoS One 4:e4717. http://dx.doi.org/10.1371/journal.pone.0004717.
17. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y. 2002. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 298:1039-1043. http://dx.doi.org/10.1126/science.1076997.
18. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. 2006. Genomewide mapping of polycomb target genes unravels their roles in cell fate transitions. Genes Dev 20:1123-1136. http://dx.doi.org/10.1101/gad.381706.
19. Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Ezponda T, Martinez-Garcia E, Zhang H, Zheng Y, Verma SK, McCabe MT, Ott HM, Van Aller GS, Kruger RG, Liu Y, McHugh CF, Scott DW, Chung YR, Kelleher N, Shaknovich R, Creasy CL, Gascoyne RD, Wong K-K, Cerchietti L, Levine RL, Abdel-Wahab O, Licht JD, Elemento O, Melnick AM. 2013. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23:677-692. http://dx.doi.org/10.1016/j.ccr.2013.04.011.
20. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, Piqani B, Eisenhaure TM, Luo B, Grenier JK, Carpenter AE, Foo SY, Stewart SA, Stockwell BR, Hacohen N, Hahn WC, Lander ES, Sabatini DM, Root DE. 2006. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124:1283-1298. http://dx.doi.org/10.1016/j.cell.2006.01.040.
21. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101. http://dx.doi.org/10.1126/science.1106148.
22. Trapnell C, Pachter L, Salzberg SL. 2009. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25:1105-1111. http://dx.doi.org/10.1093/bioinformatics/btp120.
23. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L. 2010. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28:511-515. http://dx.doi.org/10.1038/nbt.1621.
24. Tempera I, Wiedmer A, Dheekollu J, Lieberman PM. 2010. CTCF prevents the epigenetic drift of EBV latency promoter Qp. PLoS Pathog 6:e1001048. http://dx.doi.org/10.1371/journal.ppat.1001048.
25. Tempera I, Klichinsky M, Lieberman PM. 2011. EBV latency types adopt alternative chromatin conformations. PLoS Pathog 7:e1002180. http://dx.doi.org/10.1371/journal.ppat.1002180.
26. Bundred N, Gardovskis J, Jaskiewicz J, Eglitis J, Paramonov V, McCormack P, Swaisland H, Cavallin M, Parry T, Carmichael J, Dixon JM. 2013. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. Invest New Drugs 31:949-958. http://dx.doi.org/10.1007/s10637-012-9922-7.
27. Luo X, Kraus WL. 2012. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev 26:417-432. http://dx.doi.org/10.1101/gad.183509.111.
28. Goruppi S, Iovanna JL. 2010. Stress-inducible protein p8 is involved in several physiological and pathological processes. J Biol Chem 285:1577-1581. http://dx.doi.org/10.1074/jbc. R109.080887.
29. Chase A, Cross NCP. 2011. Aberrations of EZH2 in cancer. Clin Cancer Res 17:2613-2618. http://dx.doi.org/10.1158/1078-0432.CCR-10-2156.
30. Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A. 2013. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res 19:5003-5015. http://dx.doi.org/10.1158/1078-0432.CCR-13-1391.
31. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. 2003. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBOJ 22:5323-5335. http://dx.doi.org/10.1093/emboj/cdg542.
32. Lindeman GJ, Gaubatz S, Livingston DM, Ginsberg D. 1997. The subcellular localization of E2F-4 is cell-cycle dependent. Proc Natl Acad Sci U S A 94:5095-5100. http://dx.doi.org/10.1073/pnas.94.10.5095.
33. Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu H, Sun L, Zhang Y, Chen Y, Li R, Zhang Y, Zhang Y, Hong M, Shang Y. 2007. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol 27:5105-5119. http://dx.doi.org/10.1128/MCB.00162-07.
34. Lee ST, Li Z, Wu Z, Aau M, Guan P, Karuturi RKM, Liou YC, Yu Q. 2011. Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. Mol Cell 43:798-810. http://dx.doi.org/10.1016/j.molcel.2011.08.011.
35. Nuytten M, Beke L, Van Eynde A, Ceulemans H, Beullens M, Van Hummelen P, Fuks F, Bollen M. 2008. The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing. Oncogene 27:1449-1460. http://dx.doi.org/10.1038/sj.onc.1210774.
36. Su L, Sampaio AV, Jones KB, Pacheco M, Goytain A, Lin S, Poulin N, Yi L, Rossi FM, Kast J, Capecchi MR, Underhill TM, Nielsen TO. 2012. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell 21:333-347. http://dx.doi.org/10.1016/j.ccr.2012.01.010.
37. Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen YC, Peng Y, Yao KT, Kung HF, Li XP. 2011. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 71:225-233. http://dx.doi.org/10.1158/0008-5472.CAN-10-1850.
38. Whitacre CM, Hashimoto H, Tsai ML, Chatterjee S, Berger SJ, Berger NA. 1995. Involvement of NAD-poly(ADP-ribose) metabolism in p53 regulation and its consequences. Cancer Res 55:3697-3701.
39. Masutani M, Nozaki T, Wakabayashi K, Sugimura T. 1995. Role of poly(ADP-ribose) polymerase in cell-cycle checkpoint mechanisms following gamma-irradiation. Biochimie 77:462-465. http://dx.doi.org/10.1016/0300-9084(96)88161-2.
40. Beneke S, Cohausz O, Malanga M, Boukamp P, Althaus F, Burkle A. 2008. Rapid regulation of telomere length is mediated by poly(ADP-ribose) polymerase-1. Nucleic Acids Res 36:6309-6317. http://dx.doi.org/10.1093/nar/gkn615.
41. Guetg C, Scheifele F, Rosenthal F, Hottiger MO, Santoro R. 2012. Inheritance of silent rDNA chromatin is mediated by PARP1 via noncoding RNA. Mol Cell 45:790-800. http://dx.doi.org/10.1016/j.molcel.2012.01.024.
42. Ménissier de Murcia J, Ricoul M, Tartier L, Niedergang C, Huber A, Dantzer F, Schreiber V, Amé J-C, Dierich A, LeMeur M, Sabatier L, Chambon P, de Murcia G. 2003. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 22:2255-2263. http://dx.doi.org/10.1093/emboj/cdg206.
43. Dantzer F, Santoro R. 2013. The expanding role of PARPs in the establishment and maintenance of heterochromatin. FEBS J 280:3508-3518. http://dx.doi.org/10.1111/febs.12368.
44. Lund K, Adams PD, Copland M. 2014. EZH2 in normal and malignant hematopoiesis. Leukemia 28:44-49. http://dx.doi.org/10.1038/leu.2013.288.
45. Roper SJ, Chrysanthou S, Senner CE, Sienerth A, Gnan S, Murray A, Masutani M, Latos P, Hemberger M. 2014. ADP-ribosyltransferases Parp1 and Parp7 safeguard pluripotency of ES cells. Nucleic Acids Res 42:8914-8927. http://dx.doi.org/10.1093/nar/gku591.
46. Rouleau M, McDonald D, Gagné P, Ouellet ME, Droit A, Hunter JM, Dutertre S, Prigent C, Hendzel MJ, Poirier GG. 2007. PARP-3 associates with polycomb group bodies and with components of the DNA damage repair machinery. J Cell Biochem 100:385-401. http://dx.doi.org/10.1002/jcb.21051.
47. Rouleau M, Saxena V, Rodrigue A, Paquet ER, Gagnon A, Hendzel MJ, Masson J-Y, Ekker M, Poirier GG. 2011. A key role for poly(ADP-ribose) polymerase 3 in ectodermal specification and neural crest development. PLoS One 6:e15834. http://dx.doi.org/10.1371/journal.pone.0015834.
48. Sousa FG, Matuo R, Soares DG, Escargueil AE, Henriques JAP, Larsen AK, SaffiJ. 2012. PARPs and the DNA damage response. Carcinogenesis 33:1433-1440. http://dx.doi.org/10.1093/carcin/bgs132.
49. De Vos M, El Ramy R, Quénet D, Wolf P, Spada F, Magroun N, Babbio F, Schreiber V, Leonhardt H, Bonapace IM, Dantzer F. 2014. Poly(ADP-ribose) polymerase 1 (PARP1) associates with E3 ubiquitin-protein ligase UHRF1 and modulates UHRF1 biological functions. J Biol Chem 289:16223-16238. http://dx.doi.org/10.1074/jbc. M113.527424.
50. Mittelstadt PR, DeFranco AL. 1993. Induction of early response genes by cross-linking membrane Ig on B lymphocytes. J Immunol 150:4822-4832.
51. de Gorter DJJ, Vos JCM, Pals ST, Spaargaren M. 2007. The B cell antigen receptor controls AP-1 and NFAT activity through Rasmediated activation of Ral. J Immunol 178:1405-1414. http://dx.doi.org/10.4049/jimmunol.178.3.1405.
52. Minotti R, Andersson A, Hottiger MO. 2015. ARTD1 suppresses interleukin 6 expression by repressing MLL1-dependent histone H3 trimethylation. Mol Cell Biol 35:3189-3199. http://dx.doi.org/10.1128/MCB.00196-15.
53. Hock H. 2012. A complex polycomb issue: the two faces of EZH2 in cancer. Genes Dev 26:751-755. http://dx.doi.org/10.1101/gad.191163.112.